Top 5 Most-Read Breast Cancer Content of 2025

The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast cancer, unsuccessful treatment approaches, policy infrastructure affecting treatment outcomes, and preventive mammography screening.

Here are the top 5 most-viewed breast cancer pieces of 2025.

5. Atezolizumab Fails to Help in High-Risk Triple-Negative Breast Cancer

Atezolizumab, an immunotherapy drug, when combined with chemotherapy to treat patients with high-risk triple-negative breast cancer, did not improve survival outcomes and was found to be associated with a higher incidence of severe treatment-related adverse events. The study was limited in its ability to detect potential long-term benefits, and it was terminated early, which shortened the follow-up period, creating gaps in long-term safety data and observations for potential late-onset adverse events.

Read the full article.

4. Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

A population-based cohort study of Swedish-born women showed that 30% of breast cancers were missed, often emerging between scheduled appointments, pushing researchers to evaluate more personalized, risk-based screening strategies. Women who were older in age at first childbirth, had a higher education level, received hormone replacement therapy, and had a higher mammographic density were at an increased risk of interval cancer.

Read the full article.

3. Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

A retrospective cohort study of 12,349 women with local- or regional-stage breast cancer in Ohio found no overall difference in receipt of standard treatment, time to treatment initiation, or overall survival between Medicare Advantage (MA) and fee‑for‑service (FFS) Medicare. However, Black patients enrolled in FFS were less likely than Black patients in MA plans to receive standard treatment, raising equity concerns.

Read the full article.

2. FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer

The FDA approved datopotamab deruxtecan (Datroway; Daiichi Sankyo Inc), a Trop-2-directed antibody-drug conjugate, for adult patients with metastatic/HR-positive or HER2-negative breast cancer who previously received endocrine-based therapy and chemotherapy. The approval was based on findings from the TROPION-Breast01 multicenter, open-label, randomized trial, which showed a significant improvement in progression-free survival and a confirmed objective response rate that favored datopotamab deruxtecan.

Read the full article.

1. FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer

This year, the FDA also approved trastuzumab deruxtecan (Enhertu; Daiichi Sankyo Inc) for adults with metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer based on findings from the phase 3 DESTINY-Breast06 trial. Trastuzumab deruxtecan demonstrated a 36% reduction in the risk of disease progression or death when compared with chemotherapy and a significantly higher confirmed objective response rate. No new safety concerns were identified.

Read the full article.